Val-Cit-PAB-MMAF is a protease-cleavable linker-payload conjugate used in the construction of antibody-drug conjugates (ADCs). It incorporates the cytotoxic agent MMAF, which inhibits tubulin polymerization. This conjugate is a key reagent for developing targeted cancer therapeutics and is widely used in both in vitro and in vivo ADC research.